Bleb injections ward off orbital tumours

Article

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Professor Brian Mohney and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, completed a non-comparative interventional case series on two patients who presented with bilateral retinoblastoma.

Subconjunctival chemotherapy was administered to both patients to reduce the risk or orbital tumour seeding after intravitreal injection. The outcome measures were ocular toxicity levels and the presence or absence of viable tumour cells at the injection site.

Subconjunctival chemotherapy bleb injections before intravitreal drug delivery seem to reduce the risk of orbital tumour seeding in patients with advanced stage retinoblastoma.

The paper was recently published in the British Journal of Ophthalmology and is available by clicking here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.